Jun 7, 2018 Cellectar Granted U.S. Patent for the Treatment of Various Cancers and Cancer Stem Cells with CLR 131 Learn More
Jun 6, 2018 FDA Grants Rare Pediatric Disease Designation to Cellectar Biosciences’ CLR 131 for the Treatment of Rhabdomyosarcoma Learn More
May 11, 2018 Cellectar Reports Recent Corporate Highlights and 2018 First Quarter Financial Results Learn More
May 9, 2018 Cellectar Granted Orphan Drug Designation for CLR 131 to Treat Rhabdomyosarcoma Learn More